Comprehensive next-generation sequencing should be performed on Stage Ib to IIIa lung cancer tumor tissue from non-smokers because actionable genomic alterations such as EGFR variants or ALK gene rearrangements are treated with targeted therapy such as the tyrosine kinase inhibitors osimertinib or lorlatinib, respectively. This evidence concerns the gene ALK and lung cancer.